US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CG Oncology Inc.

23.74

-0.3900-1.62%

Post-market: 23.740.00000.00%17:17 EDT

Volume:1.94M

Turnover:47.35M

Market Cap:1.81B

PE:-16.85

High:25.35

Open:23.69

Low:23.52

Close:24.13

Loading ...

Overview Company News Filings

CG Oncology Announces Promising Phase 3 Trial Results

CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Buy Rating for CG Oncology, Inc. Driven by Promising Therapeutic Developments and Strong Safety Profile of Creto

Buy Rating for CG Oncology, Inc.: Promising Efficacy and Competitive Positioning in NMIBC Treatment

CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting

BRIEF-CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec

CG Oncology Inc - Cretostimogene Monotherapy Shows 42.3% Response Rate at 24 Months

THOMSON REUTERS

CG Oncology Announces Best-in-Disease Durability Data in Bond-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

THOMSON REUTERS

CG Oncology Inc - No Grade 3 or Greater Adverse Events Reported

THOMSON REUTERS

CG Oncology Inc - 97.3% Patients Free From Mibc Progression at 24 Months

THOMSON REUTERS

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

CG Oncology’s Promising Phase 3 Data and Market Potential Justify Buy Rating

U.S. RESEARCH ROUNDUP-3M, Citigroup, Nvidia

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Buy Rating Affirmed for CG Oncology Amid Promising Trial Data and Market Opportunities

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade

Stock Track | CG Oncology Plummets 5.37% Following Mixed Shelf Filing and Wider Q4 Losses

Stock Track | CG Oncology Plummets 5.37% Following Mixed Shelf Filing Announcement

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CGON/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGON","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":23.74,"timestamp":1746820800000,"preClose":24.13,"halted":0,"volume":1941794,"hourTrading":{"tag":"盘后","latestPrice":23.74,"preClose":23.74,"latestTime":"17:17 EDT","volume":437536,"amount":10387126.78,"timestamp":1746825450615},"delay":0,"floatShares":61122025,"shares":76221857,"eps":-1.408697,"marketStatus":"Market Closed","change":-0.39,"latestTime":"05-09 16:00:00 EDT","open":23.69,"high":25.345,"low":23.52,"amount":47354254.543252,"amplitude":0.075632,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.408697,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":24.13,"preHourTrading":{"tag":"盘前","latestPrice":24.69,"preClose":24.13,"latestTime":"08:36 EDT","volume":128,"amount":3161.28,"timestamp":1746794193485},"postHourTrading":{"tag":"盘后","latestPrice":23.74,"preClose":23.74,"latestTime":"17:17 EDT","volume":437536,"amount":10387126.78,"timestamp":1746825450615},"volumeRatio":0.751181340549272,"impliedVol":0.6363,"impliedVolPercentile":0.344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","floatShares":61122025,"roa":"-15.02%","roe":"-19.18%","lyrEps":-1.408697,"volumeRatio":0.751181340549272,"shares":76221857,"dividePrice":0,"high":25.345,"amplitude":0.075632,"preClose":24.13,"low":23.52,"week52Low":14.8,"pbRate":"2.47","psRate":"1588.68","week52High":40.47,"institutionHeld":0,"latestPrice":23.74,"eps":-1.408697,"divideRate":0,"volume":1941794,"delay":0,"ttmEps":-1.408697,"open":23.69,"prevYearClose":28.68,"prevWeekClose":29.05,"prevMonthClose":26.94,"prevQuarterClose":24.49,"fiveDayClose":29.05,"twentyDayClose":17.63,"sixtyDayClose":28},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGON\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530453403","title":"CG Oncology Announces Promising Phase 3 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453403","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453403?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:58","pubTimestamp":1745841533,"startTime":"0","endTime":"0","summary":"An announcement from CG Oncology, Inc. ( ($CGON) ) is now available. On April 26, 2025, CG Oncology announced promising results from its Phase 3 BO...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cg-oncology-announces-promising-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cg-oncology-announces-promising-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","BK4139","CGON","CG","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2530405870","title":"CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530405870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530405870?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:57","pubTimestamp":1745841420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2025 07:57 ET (11:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2530473434","title":"Buy Rating for CG Oncology, Inc. Driven by Promising Therapeutic Developments and Strong Safety Profile of Creto","url":"https://stock-news.laohu8.com/highlight/detail?id=2530473434","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530473434?lang=en_us&edition=fundamental","pubTime":"2025-04-28 18:16","pubTimestamp":1745835393,"startTime":"0","endTime":"0","summary":"Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-driven-by-promising-therapeutic-developments-and-strong-safety-profile-of-creto?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-driven-by-promising-therapeutic-developments-and-strong-safety-profile-of-creto?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2530491612","title":"Buy Rating for CG Oncology, Inc.: Promising Efficacy and Competitive Positioning in NMIBC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2530491612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530491612?lang=en_us&edition=fundamental","pubTime":"2025-04-28 09:55","pubTimestamp":1745805311,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a pric...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-promising-efficacy-and-competitive-positioning-in-nmibc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cg-oncology-inc-promising-efficacy-and-competitive-positioning-in-nmibc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2530657754","title":"CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530657754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530657754?lang=en_us&edition=fundamental","pubTime":"2025-04-28 05:20","pubTimestamp":1745788821,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cg-oncology-announces-phase-3-bond-003-data-presented-at-aua-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cg-oncology-announces-phase-3-bond-003-data-presented-at-aua-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","US3Y.BOND","CGON","IE00B64PRP62.GBP","BOND","BK4585","US30Y.BOND","US5Y.BOND","US7Y.BOND","CG","BK4135","US2Y.BOND","US10Y.BOND","BK4588","US6M.BOND","US12M.BOND"],"gpt_icon":0},{"id":"2530117936","title":"BRIEF-CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec","url":"https://stock-news.laohu8.com/highlight/detail?id=2530117936","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530117936?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:12","pubTimestamp":1745698340,"startTime":"0","endTime":"0","summary":"BRIEF-CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene GrenadenorepvecApril 26 (Reuters) - CG Oncology Inc CGON.O:CG O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA5XJ7GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2530793651","title":"CG Oncology Inc - Cretostimogene Monotherapy Shows 42.3% Response Rate at 24 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2530793651","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530793651?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA5XJ7GB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2530793501","title":"CG Oncology Announces Best-in-Disease Durability Data in Bond-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530793501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530793501?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA5XJ7GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2530179366","title":"CG Oncology Inc - No Grade 3 or Greater Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2530179366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530179366?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA5XJ7GB:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2530179357","title":"CG Oncology Inc - 97.3% Patients Free From Mibc Progression at 24 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2530179357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530179357?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA5XJ7GB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2530171196","title":"CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530171196","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530171196?lang=en_us&edition=fundamental","pubTime":"2025-04-27 04:10","pubTimestamp":1745698200,"startTime":"0","endTime":"0","summary":"- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C –。- 58.3% of patients showed durable complete responses by K-M at 24 months –。- 97.3% of all treated patients remained free from progression to MIBC at 24 months–。- 91.6% of responders remained cystectomy-free at 24 months –。- No Grade 3 or greater treatment-related adverse events or deaths reported –。- Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M –。- Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 -. IRVINE, Calif., April 26, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-announces-best-disease-201000079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BK4585","US7Y.BOND","CGON","IE00BGHQF748.EUR","CR","US3Y.BOND","US6M.BOND","US10Y.BOND","BK4139","AFG","BK4135","US30Y.BOND","BK4588","BK4117","US2Y.BOND","BK4161","BCG","CG","BOND","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","US5Y.BOND","US12M.BOND"],"gpt_icon":0},{"id":"2529986685","title":"CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986685","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986685?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., April 24, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer  to be presented on April 26, 2025, at a Plenary Session at the American Urological Association  Annual Meeting in Las Vegas, Nevada.About Bladder CancerMore than 85,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly diagnosed cases. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three quarters of newly diagnosed cases.Cretostimogene is an investigational, intravesical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-host-conference-call-120000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","US30Y.BOND","IE00B3QW5Z07.USD","CG","US6M.BOND","BK4218","BK4585","US7Y.BOND","BK4181","IE00BGHQF748.EUR","US10Y.BOND","HST","BOND","US3Y.BOND","BK4588","BK4135","IE00B64PRP62.GBP","US5Y.BOND","US2Y.BOND","CGON","BCG","US12M.BOND"],"gpt_icon":0},{"id":"2528586130","title":"CG Oncology’s Promising Phase 3 Data and Market Potential Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2528586130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528586130?lang=en_us&edition=fundamental","pubTime":"2025-04-20 22:06","pubTimestamp":1745157975,"startTime":"0","endTime":"0","summary":"Sean Laaman, an analyst from Morgan Stanley, reiterated the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated price target r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cg-oncologys-promising-phase-3-data-and-market-potential-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cg-oncologys-promising-phase-3-data-and-market-potential-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","CG"],"gpt_icon":0},{"id":"2527525939","title":"U.S. RESEARCH ROUNDUP-3M, Citigroup, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2527525939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527525939?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:47","pubTimestamp":1744789663,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-3M, Citigroup, Nvidia April 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including 3M, Citigroup and N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4N3QU0JT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPAM","GGG","JBHT","LU0256863902.USD","FTV","IE00BQXX3F31.USD","CGON","AME","CPAY","KREF","LU1721427968.SGD","MMM","GTES","CCNE","DOV","NLY","CARR","FLS","CAH","IE00BN0W2T93.GBP","LU1496350171.SGD","BXMT","ATO","MCK","HWC","ABR","BE","FLNC","IE00B42XCP33.USD","LII","LNN","EMR","FBK","IBKR","BMI","KRRO","HON","AOS","GO","AGNC","IEX","LU1934455863.HKD","BK4533","ARI","BOW","COR","LU0640476718.USD","LU2468319806.SGD","AXTA"],"gpt_icon":1},{"id":"2526052630","title":"How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526052630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526052630?lang=en_us&edition=fundamental","pubTime":"2025-04-11 17:30","pubTimestamp":1744363800,"startTime":"0","endTime":"0","summary":"The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr. shake-up of the nation's health agencies and persistently high interest rates are prompting it to sink even faster than the broader market, despite so far avoiding the worst of the tariff fallout.More investors are even wondering if the whole model -- risky science, costly funding, political uncertainty and long waits for payoffs -- is simply broken. For many of the nearly 200 companies trading below their cash value, it probably is. That illustrates the pitfalls of passively investing in an index for this sector.Despite that bleak backdrop, there are still some opportunities for patient investors. After all, the U.S. is still the top spender on drugs by far. And that isn't something RFK Jr. or President Trump is likely to change.\"We lost our leadership in semiconductors, and we are close to losing that position in biotech if we don'","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203201768.USD","LU1868836914.USD","SG9999017495.SGD","SG9999018865.SGD","LU0061475181.USD","LU0889565916.HKD","GILD","LU0256863902.USD","LU0882574139.USD","SG9999014906.USD","LU2471134523.USD","XBI","IE00B3T34201.USD","LU1267930730.SGD","IE00BZ9MQY76.HKD","SG9999015945.SGD","LU0823416689.USD","LU1814569148.SGD","LU0106261372.USD","IE00BJLML261.HKD","LU1035775433.USD","IE00BKVL7J92.USD","LU1069344957.HKD","LU1551013425.SGD","SGXZ57979304.SGD","GB00BDT5M118.USD","IE0002270589.USD","LU0471298694.HKD","LU2324357040.USD","LU0289739699.SGD","LU0198837287.USD","LU0256863811.USD","CGON","LU2362541273.HKD","LU0640476718.USD","ALNY","LU2237443549.SGD","LU2491050154.USD","LU2750360641.GBP","LU1712237335.SGD","LU2462157665.USD","CYTK","VRTX","BBIO","LU2552382058.USD","LU2360106947.USD","BK4505","LU2237443978.SGD","LU0354030511.USD"],"gpt_icon":1},{"id":"2526266498","title":"Buy Rating Affirmed for CG Oncology Amid Promising Trial Data and Market Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2526266498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526266498?lang=en_us&edition=fundamental","pubTime":"2025-04-09 05:35","pubTimestamp":1744148109,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-cg-oncology-amid-promising-trial-data-and-market-opportunities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-cg-oncology-amid-promising-trial-data-and-market-opportunities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGON","CG"],"gpt_icon":0},{"id":"2524924284","title":"Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2524924284","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524924284?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:55","pubTimestamp":1743429304,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc.  closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $68.14 indicates a 157.9% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $9.87. While the lowest estimate of $55 indicates a 108.2% increase from the current price level, the most optimistic analyst expects the stock to surge 214.2% to reach $83. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-believe-cg-135504983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BGHQF748.EUR","BK4135","IE00B64PRP62.GBP","CG","IE00B3QW5Z07.USD","CGON"],"gpt_icon":0},{"id":"1171562248","title":"Stock Track | CG Oncology Plummets 5.37% Following Mixed Shelf Filing and Wider Q4 Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1171562248","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171562248?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:34","pubTimestamp":1743428069,"startTime":"0","endTime":"0","summary":"Shares of CG Oncology Inc.  plummeted 5.37% in pre-market trading on Monday, as investors reacted to the company's recent mixed shelf registration filing and disappointing fourth-quarter results.The late-stage clinical biopharmaceutical company, focused on developing bladder cancer treatments, filed a registration statement on Friday for the potential sale of an unspecified amount of securities. This move, which could lead to the issuance of additional shares and potential dilution of existing s","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CGON"],"gpt_icon":0},{"id":"1138863599","title":"Stock Track | CG Oncology Plummets 5.37% Following Mixed Shelf Filing Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1138863599","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138863599?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:34","pubTimestamp":1743428064,"startTime":"0","endTime":"0","summary":"Shares of CG Oncology Inc.  plummeted 5.37% in pre-market trading on Monday following the company's announcement of a mixed shelf filing. The late-stage clinical biopharmaceutical company, focused on developing bladder cancer treatments, filed a registration statement on Friday for the potential sale of an unspecified amount of securities.The mixed shelf filing covers the sale of CG Oncology's common stock, preferred stock, debt securities, and warrants. While the company stated that the proceed","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | CG Oncology Plummets 5.37% Following Mixed Shelf Filing Announcement","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CGON"],"gpt_icon":0},{"id":"2523456589","title":"CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523456589","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523456589?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052232/0/en/CG-Oncology-to-Participate-in-the-120th-American-Urological-Association-Annual-Meeting-with-a-Series-of-Key-Presentations-and-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4135","BK4117","IE00BGHQF748.EUR","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","CGON","CG","BCG","BK4107"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGON\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-28","symbol":"CGON","fiscalQuarterEnding":"2024/12","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2024-11-12","symbol":"CGON","fiscalQuarterEnding":"2024/09","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGON\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGON\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.8,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":10,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CGON\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CGON","date":"2025-05-09","current":-20.891121,"percent":0.934211,"low":-77.942097,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"high":-13.496527,"avg":-39.939836,"sd":14.118091,"marketCap":1839233409},"quantilePoints":[{"date":"2024-01-26","current":-62.124194,"twenty":-62.124194,"median":-62.124194,"eighty":-62.124194,"marketCap":2539823423},{"date":"2024-02-02","current":-61.712969,"twenty":-61.712969,"median":-60.379514,"eighty":-59.355029,"marketCap":2523011292},{"date":"2024-02-09","current":-63.452965,"twenty":-62.124194,"median":-60.590915,"eighty":-59.355029,"marketCap":2594147579},{"date":"2024-02-16","current":-77.177799,"twenty":-70.608092,"median":-61.918582,"eighty":-60.168112,"marketCap":3155259972},{"date":"2024-02-23","current":-75.080046,"twenty":-72.448911,"median":-64.672589,"eighty":-60.20714,"marketCap":3069497532},{"date":"2024-03-01","current":-72.705845,"twenty":-73.870179,"median":-70.608092,"eighty":-60.516111,"marketCap":2972433066},{"date":"2024-03-08","current":-64.818944,"twenty":-72.891228,"median":-69.827533,"eighty":-60.799064,"marketCap":2649992888},{"date":"2024-03-15","current":-60.493345,"twenty":-72.302556,"median":-67.469593,"eighty":-60.20714,"marketCap":2473149409},{"date":"2024-03-22","current":-66.867912,"twenty":-72.162706,"median":-65.355579,"eighty":-60.438055,"marketCap":2733760852},{"date":"2024-03-28","current":-56.207672,"twenty":-71.967566,"median":-64.762028,"eighty":-59.842879,"marketCap":2732086332},{"date":"2024-04-05","current":-51.752186,"twenty":-71.648838,"median":-63.50175,"eighty":-58.14191,"marketCap":2515518513},{"date":"2024-04-12","current":-54.631116,"twenty":-71.284577,"median":-62.382039,"eighty":-56.136384,"marketCap":2655454642},{"date":"2024-04-19","current":-48.420853,"twenty":-71.001624,"median":-61.712969,"eighty":-54.576279,"marketCap":2353592420},{"date":"2024-04-26","current":-49.627262,"twenty":-70.73168,"median":-60.54213,"eighty":-53.208102,"marketCap":2412232322},{"date":"2024-05-03","current":-54.151294,"twenty":-70.286112,"median":-60.183337,"eighty":-53.600185,"marketCap":2632131954},{"date":"2024-05-10","current":-35.176138,"twenty":-69.778748,"median":-59.371617,"eighty":-52.278619,"marketCap":2000537303},{"date":"2024-05-17","current":-36.289307,"twenty":-68.393255,"median":-58.232975,"eighty":-49.860318,"marketCap":2063845445},{"date":"2024-05-24","current":-35.140985,"twenty":-67.52163,"median":-57.330453,"eighty":-49.032283,"marketCap":1998538098},{"date":"2024-05-31","current":-40.179539,"twenty":-67.228921,"median":-56.207672,"eighty":-47.173317,"marketCap":2285090743},{"date":"2024-06-07","current":-40.894311,"twenty":-66.477632,"median":-55.878652,"eighty":-42.192617,"marketCap":2325741235},{"date":"2024-06-14","current":-40.788853,"twenty":-65.885708,"median":-55.522213,"eighty":-41.278647,"marketCap":2319743621},{"date":"2024-06-21","current":-37.625109,"twenty":-65.85969,"median":-54.631116,"eighty":-40.788853,"marketCap":2139815216},{"date":"2024-06-28","current":-35.445642,"twenty":-65.443392,"median":-54.494024,"eighty":-40.683395,"marketCap":2015864537},{"date":"2024-07-05","current":-36.125261,"twenty":-64.796178,"median":-54.151294,"eighty":-39.560851,"marketCap":2054515824},{"date":"2024-07-12","current":-40.378738,"twenty":-64.675841,"median":-53.136814,"eighty":-38.206301,"marketCap":2296419569},{"date":"2024-07-15","current":-41.491907,"twenty":-64.64657,"median":-52.780375,"eighty":-38.236766,"marketCap":2359727711},{"date":"2024-08-02","current":-39.652248,"twenty":-64.6173,"median":-52.752957,"eighty":-38.267232,"marketCap":2255102676},{"date":"2024-08-09","current":-38.949194,"twenty":-63.924553,"median":-51.752186,"eighty":-38.000071,"marketCap":2215118586},{"date":"2024-08-16","current":-40.572681,"twenty":-63.472479,"median":-49.956283,"eighty":-38.105529,"marketCap":2307449488},{"date":"2024-08-23","current":-42.377221,"twenty":-62.965116,"median":-49.723226,"eighty":-38.189896,"marketCap":2410077328},{"date":"2024-08-30","current":-43.2618,"twenty":-62.33047,"median":-48.934948,"eighty":-38.276606,"marketCap":2460385093},{"date":"2024-09-06","current":-44.299706,"twenty":-62.063778,"median":-48.270052,"eighty":-38.375033,"marketCap":2519412871},{"date":"2024-09-13","current":-41.079839,"twenty":-61.869081,"median":-45.980618,"eighty":-38.588613,"marketCap":2336292606},{"date":"2024-09-20","current":-46.127835,"twenty":-61.368222,"median":-44.806865,"eighty":-38.861791,"marketCap":2623382252},{"date":"2024-09-27","current":-43.379744,"twenty":-60.747027,"median":-44.736098,"eighty":-39.046612,"marketCap":2467092795},{"date":"2024-10-04","current":-42.412604,"twenty":-60.551887,"median":-44.517902,"eighty":-39.324835,"marketCap":2412089639},{"date":"2024-10-11","current":-40.667036,"twenty":-60.382766,"median":-44.458898,"eighty":-39.52313,"marketCap":2312815649},{"date":"2024-10-18","current":-43.356155,"twenty":-60.203473,"median":-44.063818,"eighty":-39.574912,"marketCap":2465751255},{"date":"2024-10-25","current":-42.990529,"twenty":-60.177247,"median":-43.698192,"eighty":-39.657154,"marketCap":2444957379},{"date":"2024-10-31","current":-42.837202,"twenty":-60.01213,"median":-43.662809,"eighty":-39.673778,"marketCap":2436237366},{"date":"2024-11-08","current":-46.068863,"twenty":-59.381569,"median":-43.651015,"eighty":-39.804577,"marketCap":2620028401},{"date":"2024-11-15","current":-32.980568,"twenty":-59.208121,"median":-43.63922,"eighty":-39.654701,"marketCap":2400853462},{"date":"2024-11-22","current":-30.044833,"twenty":-58.542987,"median":-43.538968,"eighty":-38.997903,"marketCap":2187143689},{"date":"2024-11-29","current":-32.283796,"twenty":-58.232975,"median":-43.444613,"eighty":-38.328163,"marketCap":2350131206},{"date":"2024-12-06","current":-31.17825,"twenty":-58.005312,"median":-43.379744,"eighty":-38.000071,"marketCap":2269651893},{"date":"2024-12-13","current":-26.821099,"twenty":-57.745125,"median":-43.279491,"eighty":-37.543086,"marketCap":1952468717},{"date":"2024-12-20","current":-26.031423,"twenty":-56.915781,"median":-43.120267,"eighty":-36.394765,"marketCap":1894983493},{"date":"2024-12-27","current":-27.044066,"twenty":-56.349294,"median":-43.061296,"eighty":-36.125261,"marketCap":1968699839},{"date":"2025-01-03","current":-26.914002,"twenty":-56.207672,"median":-43.037707,"eighty":-35.33784,"marketCap":1959231684},{"date":"2025-01-10","current":-28.298257,"twenty":-56.136384,"median":-42.978735,"eighty":-34.953504,"marketCap":2059999900},{"date":"2025-01-17","current":-27.034776,"twenty":-55.969133,"median":-42.872585,"eighty":-33.374909,"marketCap":1968023542},{"date":"2025-01-24","current":-32.158189,"twenty":-55.840266,"median":-42.689773,"eighty":-32.852839,"marketCap":2340987506},{"date":"2025-01-31","current":-31.530712,"twenty":-55.653821,"median":-42.565931,"eighty":-32.283796,"marketCap":2295309701},{"date":"2025-02-07","current":-31.405216,"twenty":-55.437216,"median":-42.394913,"eighty":-32.036945,"marketCap":2286174140},{"date":"2025-02-14","current":-29.805151,"twenty":-55.004006,"median":-42.206678,"eighty":-31.677123,"marketCap":2169695737},{"date":"2025-02-21","current":-29.512328,"twenty":-54.631116,"median":-41.999801,"eighty":-31.530712,"marketCap":2148379428},{"date":"2025-02-28","current":-25.768383,"twenty":-54.494024,"median":-41.775708,"eighty":-31.373843,"marketCap":1875835192},{"date":"2025-03-07","current":-28.226,"twenty":-54.39406,"median":-41.609082,"eighty":-31.094637,"marketCap":2054739928},{"date":"2025-03-14","current":-27.138374,"twenty":-54.151294,"median":-41.292708,"eighty":-30.560445,"marketCap":1975565066},{"date":"2025-03-21","current":-29.020804,"twenty":-53.671473,"median":-41.068045,"eighty":-30.21301,"marketCap":2112598481},{"date":"2025-03-28","current":-28.173711,"twenty":-53.493253,"median":-40.922206,"eighty":-29.826066,"marketCap":2050933444},{"date":"2025-04-04","current":-16.223536,"twenty":-52.780375,"median":-40.788853,"eighty":-29.478125,"marketCap":1428303862},{"date":"2025-04-11","current":-15.26259,"twenty":-52.725539,"median":-40.592885,"eighty":-29.073094,"marketCap":1343703153},{"date":"2025-04-17","current":-17.504797,"twenty":-52.648767,"median":-40.36956,"eighty":-28.807616,"marketCap":1541104808},{"date":"2025-04-25","current":-18.630229,"twenty":-51.927664,"median":-39.710836,"eighty":-28.715432,"marketCap":1640186719},{"date":"2025-05-02","current":-24.014988,"twenty":-51.631545,"median":-39.587801,"eighty":-28.276198,"marketCap":2114255557},{"date":"2025-05-09","current":-20.891121,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"marketCap":1839233409}],"updateTime":1746975859825}}}